Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant plus Pembrolizumab in Advanced Adrenocortical Carcinoma
NCT04373265Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Sep 2020
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relacorilant in adrenocortical carcinoma (ACC), sponsored by Corcept Therapeutics. Primary endpoint: Dose-limiting Toxicity at 12 weeks. Started Sep 2020; status: completed.
02
Drugs
relacorilant
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT04373265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04373265.